Newsroom | 19866 results

DUBLIN--(BUSINESS WIRE)--Prothena reported financial results for the second quarter and first six months of 2026 and provided business highlights....

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced that company management will participate in the Canaccord Genuity and Wells Fargo investor conferences....

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2026. Recent Financial Highlights Generated total revenues of $752.8 million in the second quarter of 2026, compared to $546.6 million in the second quarter of 2025, an increase of 37.7%. Generated a gross margin1 of 64.5% in the second quarter of 2026, compared to a gross margin1 of 63.4% in the second quar...

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2026, together with other business updates. Key Financial Results: Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million; Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 milli...

DALLAS--(BUSINESS WIRE)--The Colossal Foundation, the 501(c)(3) charitable organization of Colossal Biosciences, has announced the second cohort of its Species Reintroduction Fund, expanding the program to seven new species across four continents. In collaboration with the global conservation nonprofit Re:wild, the Fund will direct its annual commitment of $250,000 to teams working in Cambodia, the United States, Brazil, Guatemala, Australia, and Canada. Launched in 2025 as the first fund in th...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced that it has been Certified™ by Great Place To Work® for July 2026-2027. The prestigious award is based entirely on what current employees say about their experience working at SMPA. This year, 89% of company employees said SMPA is a great place to work – compared to just 57% of employees at the average U.S. company. “When employees have a positive perception of the company, it becomes a powerful driver of...

HOUSTON--(BUSINESS WIRE)--IPS HEART, Inc., a biopharmaceutical company pioneering induced pluripotent stem cell (iPSC)-derived cell replacement therapies, announced that the FDA has granted Rare Pediatric Drug Designation for ISX9-CPC, for the treatment of cardiomyopathies associated with dystrophinopathies. Redefining the Therapeutic Paradigm: Generating New Human Muscle Duchenne muscular dystrophy (DMD) leads to progressive skeletal muscle loss, severe cardiac fibrosis, and premature death fr...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--ReCode Therapeutics Announces New Funding from the Cystic Fibrosis Foundation, Collaboration with Leading Gene Editing Company & Leadership Transition...

BOSTON--(BUSINESS WIRE)--PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights...

BOSTON--(BUSINESS WIRE)--PepGen to Advance PGN-EDODM1 into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review...